The Chicago Entrepreneur

: Compass shares jump as study shows psychedelic-based drug improved depression in cancer patients

Compass shares rose 3% after the London-based mental-health care group reported in a follow-up study that its COMP360 psilocybin treatment, alongside psychological support, led to remission of depression in most cancer patients.

Previous post Market Extra: ‘The economy is still too hot for the Fed’: Chance of June rate hike rises further above 50% after inflation data
Next post Ford’s EV charging deal with Tesla puts pressure on GM, other rival automakers